{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:09:29Z","timestamp":1790986169381,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bioorg.2023.106502","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T03:31:45Z","timestamp":1680233505000},"page":"106502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs"],"prefix":"10.1016","volume":"135","author":[{"given":"Aya Y.","family":"Rashad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda G.","family":"Daabees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elagawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.","family":"Abdel Moneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif A.F.","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106502_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/CIA.S5476","article-title":"Management of hyperuricemia in gout: Focus on febuxostat","volume":"5","author":"Reinders","year":"2010","journal-title":"Clin. Interv. Aging."},{"key":"10.1016\/j.bioorg.2023.106502_b0010","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.bcp.2013.08.011","article-title":"3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: A potential therapeutic agent for treatment of hyperuricemia and gout","volume":"86","author":"L\u00fc","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106502_b0015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bmcl.2017.01.049","article-title":"Discovery and biological evaluation of some (1H\u20131,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety as potent xanthine oxidase inhibitors","volume":"27","author":"Zhang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106502_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114092","article-title":"Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia","volume":"229","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bmc.2012.09.060","article-title":"Trisubstituted thiophene analogues of 1-thiazolyl-2-pyrazoline, super oxidase inhibitors and free radical scavengers","volume":"21","author":"Mandawad","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bioorg.2023.106502_b0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2007.04.004","article-title":"The inflammasome, autoinflammatory diseases, and gout","volume":"74","author":"P\u00e9trilli","year":"2007","journal-title":"Jt. Bone Spine."},{"key":"10.1016\/j.bioorg.2023.106502_b0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000585","article-title":"Gout and cardiovascular disease: Crystallized confusion","volume":"31","author":"Abeles","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bioorg.2023.106502_b0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MNH.0000000000000619","article-title":"The role of uric acid in inflammasome-mediated kidney injury","volume":"29","author":"Braga","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bioorg.2023.106502_b0050","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/rheumatology\/kez476","article-title":"Global, regional and national burden of gout, 1990\u20132017: a systematic analysis of the Global Burden of Disease Study","volume":"59","author":"Xia","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.bioorg.2023.106502_b0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejmech.2018.06.009","article-title":"Design, synthesis and bioevaluation of 2-mercapto-6-phenylpyrimidine-4-carboxylic acid derivatives as potent xanthine oxidase inhibitors","volume":"155","author":"Shi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0060","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ejmech.2018.01.096","article-title":"Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo[b]furan scaffold","volume":"151","author":"Tang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/2040622312462056","article-title":"Latest evidence on gout management: what the clinician needs to know","volume":"3","author":"Burns","year":"2012","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.bioorg.2023.106502_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126944","article-title":"Development of novel NLRP3-XOD dual inhibitors for the treatment of gout","volume":"30","author":"Wang","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106502_b0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejmech.2012.08.030","article-title":"Synthesis and evaluation of mutual prodrugs of ibuprofen with menthol, thymol and eugenol","volume":"56","author":"Redasani","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105101","article-title":"Synthesis and biological evaluation of new prodrugs of etodolac and tolfenamic acid with reduced ulcerogenic potential","volume":"140","author":"Hassib","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106502_b0085","first-page":"46","article-title":"Ester Prodrugs of Ketoprofen: Synthesis, Hydrolysis Kinetics and Pharmacological Evaluation","volume":"66","author":"Dhokchawle","year":"2016","journal-title":"Drug Res."},{"key":"10.1016\/j.bioorg.2023.106502_b0090","doi-asserted-by":"crossref","first-page":"17244","DOI":"10.3390\/ijms131217244","article-title":"Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review","volume":"13","author":"Qandil","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2023.106502_b0095","doi-asserted-by":"crossref","first-page":"1800339","DOI":"10.1002\/ardp.201800339","article-title":"Novel ketoprofen\u2013antioxidants mutual codrugs as safer nonsteroidal anti-inflammatory drugs: Synthesis, kinetic and pharmacological evaluation","volume":"352","author":"Sehajpal","year":"2019","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2023.106502_b0100","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1021\/acs.jmedchem.6b00220","article-title":"Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400)","volume":"59","author":"Lv","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14756360600988831","article-title":"Synthesis and in vitro anti-HIV activities of didanosine prodrugs","volume":"22","author":"Sriram","year":"2007","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0110","first-page":"812","article-title":"Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-\u03b1 and COX-2","volume":"17","author":"Hao","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bioorg.2023.106502_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105884","article-title":"Febuxostat attenuates ulcerative colitis by the inhibition of NF-\u03baB, proinflammatory cytokines, and oxidative stress in mice","volume":"76","author":"Amirshahrokhi","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2023.106502_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104948","article-title":"Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies","volume":"113","author":"Rashad","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0125","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.3390\/ijms20225635","article-title":"Anti-Inflammatory and Anti-Hyperuricemic Functions of Two Synthetic Hybrid Drugs with Dual Biological Active Sites","volume":"20","author":"Almeer","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2023.106502_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2021.101733","article-title":"Anti-inflammatory drugs as new inhibitors to xanthine oxidase: In vitro and in silico approach","volume":"58","author":"Bou-Salah","year":"2021","journal-title":"Mol. Cell. Probes."},{"key":"10.1016\/j.bioorg.2023.106502_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105938","article-title":"Design, synthesis and biological evaluation of N-(4-alkoxy-3-(1H-tetrazol-1-yl)phenyl) heterocyclic aromatic amide derivatives as xanthine oxidase inhibitors","volume":"127","author":"Zhang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105181","article-title":"N-(3-cyano-1H-indol-5-yl)isonicotinamide and N-(3-cyano-1H-indol-5-yl)-1H-benzo[d]imidazole-5-carboxamide derivatives: Novel amide-based xanthine oxidase inhibitors","volume":"115","author":"Tu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.618411","article-title":"Advances in Oral Drug Delivery","volume":"12","author":"Alqahtani","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106502_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134240","article-title":"Synthesis, analgesic, anti-inflammatory, ulcerogenic evaluation, and docking study of (benzoylphenoxy)-N-{5-[2-methylphenyl-6-chlorobenzoxazole]} acetamides as COX\/5-LOX inhibitor","author":"Nagesh Khadri","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2023.106502_b0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2005.09.006","article-title":"Nonsteroidal antiinflammatory agents-part 2 antiinflammatory, analgesic and antipyretic activity of some substituted 3-pyrazolin-5-ones and 1,2,4,5,6,7\u20133H-hexahydroindazol-3-ones","volume":"41","author":"El-Hawash","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104555","article-title":"Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies","volume":"108","author":"Alfayomy","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105627","article-title":"Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study","volume":"120","author":"Abdellatif","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0170","series-title":"Isozymes: Molecular Structure","author":"Markert","year":"2012"},{"key":"10.1016\/j.bioorg.2023.106502_b0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2006.11.047","article-title":"In vitro evaluation of dendrimer prodrugs for oral drug delivery","volume":"336","author":"Najlah","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2023.106502_b0180","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3109\/03639045.2011.560155","article-title":"A promising codrug of nicotinic acid and ibuprofen for managing dyslipidemia. I: synthesis and in vitro evaluation, Drug Dev","volume":"37","author":"Abu Zanat","year":"2011","journal-title":"Ind. Pharm."},{"key":"10.1016\/j.bioorg.2023.106502_b0185","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/jm101095e","article-title":"Synthesis, characterization, and biological evaluation of novel diclofenac prodrugs","volume":"54","author":"Bandgar","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.22159\/ijap.2019v11i1.30539","article-title":"Solid dispersion technique to enhance the solubility and dissolution of febuxostat an BCS class II drug","volume":"11","author":"Christopher Vimalson","year":"2019","journal-title":"Int. J. Appl. Pharm."},{"key":"10.1016\/j.bioorg.2023.106502_b0195","unstructured":"SwissADME, (n.d.). http:\/\/www.swissadme.ch\/."},{"key":"10.1016\/j.bioorg.2023.106502_b0200","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1016\/j.bmcl.2014.07.058","article-title":"Design, synthesis, in silico and in vitro studies of novel 4-methylthiazole-5-carboxylic acid derivatives as potent anti-cancer agents","volume":"24","author":"Kilaru","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106502_b0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/03639045.2013.767828","article-title":"Evaluation of diclofenac prodrugs for enhancing transdermal delivery","volume":"40","author":"Lobo","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.bioorg.2023.106502_b0210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: Towards prediction paradise?","volume":"2","author":"van de Waterbeemd","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2023.106502_b0215","unstructured":"Molsoft L.L.C., (n.d.). https:\/\/www.molsoft.com\/."},{"key":"10.1016\/j.bioorg.2023.106502_b0220","unstructured":"Molinspiration, Cheminformatics (n.d.). https:\/\/www.molinspiration.com\/."},{"key":"10.1016\/j.bioorg.2023.106502_b0225","unstructured":"PreADMET, (n.d.). https:\/\/preadmet.bmdrc.kr\/."},{"key":"10.1016\/j.bioorg.2023.106502_b0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2023.106502_b0235","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1023\/A:1020444330011","article-title":"Rate-limited steps of human oral absorption and QSAR studies","volume":"19","author":"Zhao","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2023.106502_b0240","doi-asserted-by":"crossref","unstructured":"P.A. Elzahhar, S.M. Abd El Wahab, M. Elagawany, H. Daabees, A.S.F. Belal, A.F. EL-Yazbi, A.H. Eid, R. Alaaeddine, R.R. Hegazy, R.M. Allam, M.W. Helmy, Bahaa Elgendy, A. Angeli, S.A. El-Hawash, C.T. Supuran, Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases Eur. J. Med. Chem. 200 (2020) 112439.","DOI":"10.1016\/j.ejmech.2020.112439"},{"key":"10.1016\/j.bioorg.2023.106502_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104556","article-title":"QM\/MM analysis, synthesis and biological evaluation of epalrestat based mutual-prodrugs for diabetic neuropathy and nephropathy","volume":"108","author":"Choudhary","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2011.03.012","article-title":"Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile","volume":"43","author":"Qandil","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106502_b0255","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm101085j","article-title":"Synthesis and Biological Evaluation of Orally Active Prodrugs of Indomethacin","volume":"54","author":"Bandgar","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0260","first-page":"727","article-title":"Interaction of palladium inorganic salt and organic complex with glutathione content of liver homogenate","volume":"31","author":"Mukhtiar","year":"2018","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106502_b0265","article-title":"Design, synthesis and pharmacological evaluation of CVIB, a codrug of carvacrol and ibuprofen as a novel anti-inflammatory agent","volume":"76","author":"de Oliveira Pedrosa","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2023.106502_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114515","article-title":"Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration","volume":"238","author":"Antraygues","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106502_b0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejmech.2012.08.036","article-title":"Synthesis and biological evaluation of ester prodrugs of benzafibrate as orally active hypolipidemic agents","volume":"57","author":"Bandgar","year":"2012","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823001621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823001621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:43:40Z","timestamp":1758617020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823001621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":55,"alternative-id":["S0045206823001621"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106502","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106502"}}